首页> 外文期刊>Nanotechnology >Galactosylated manganese ferrite nanoparticles for targeted MR imaging of asialoglycoprotein receptor
【24h】

Galactosylated manganese ferrite nanoparticles for targeted MR imaging of asialoglycoprotein receptor

机译:半乳糖基化锰铁氧体纳米颗粒用于去唾液酸糖蛋白受体的MR靶向成像

获取原文
获取原文并翻译 | 示例
           

摘要

Cancer cells can express specific biomarkers, such as cell membrane proteins and signaling factors. Thus, finding biomarkers and delivering diagnostic agents are important in the diagnosis of cancer. In this study, we investigated a biomarker imaging agent for the diagnosis of hepatic cancers. The asialoglycoprotein receptor (ASGPr) was selected as a biomarker for hepatoma cells and the ASGPr-targetable imaging agent bearing a galactosyl group was prepared using manganese ferrite nanoparticles (MFNP) and galactosylgluconic acid. The utility of the ASGPr-targetable imaging agent, galactosylated MFNP (G-MFNP) was assessed by several methods in ASGPr-expressing HepG2 cells as target cells and ASGPr-deficient MCF7 cells. Physical and chemical properties of G-MFNP were examined using Fourier-transform infrared spectroscopy, dynamic light scattering, zeta potential analysis, and transmission electron microscopy. No significant cytotoxicity was observed in either cell line. Targeting ability was assessed using flow cytometry, magnetic resonance imaging, inductively coupled plasma atomic emission spectroscopy, absorbance analysis, dark-field microscopy, Prussian blue staining, and transmission electron microscopy. We demonstrated that G-MFNP target successfully and bind to ASGPr-expressing HepG2 cells specifically. We suggest that these results will be useful in strategies for cancer diagnoses based on magnetic resonance imaging.
机译:癌细胞可以表达特定的生物标志物,例如细胞膜蛋白和信号传导因子。因此,发现生物标志物和递送诊断剂在癌症的诊断中很重要。在这项研究中,我们研究了一种用于肝癌诊断的生物标志物成像剂。选择无唾液酸糖蛋白受体(ASGPr)作为肝癌细胞的生物标志物,并使用锰铁氧体纳米颗粒(MFNP)和半乳糖基葡萄糖酸制备带有半乳糖基的ASGPr靶向显像剂。通过多种方法评估了表达ASGPr的HepG2细胞作为靶细胞和缺少ASGPr的MCF7细胞的ASGPr靶向成像剂,半乳糖基化MFNP(G-MFNP)的实用性。使用傅立叶变换红外光谱,动态光散射,ζ电位分析和透射电子显微镜检查了G-MFNP的物理和化学性质。在任一细胞系中均未观察到明显的细胞毒性。使用流式细胞仪,磁共振成像,电感耦合等离子体原子发射光谱法,吸光度分析,暗视野显微镜,普鲁士蓝染色和透射电子显微镜对靶向能力进行评估。我们证明了G-MFNP成功地靶向并与表达ASGPr的HepG2细胞特异性结合。我们建议这些结果将有助于基于磁共振成像的癌症诊断策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号